DF/HCC New Member

Please welcome Dr. Hur who recently joined DF/HCC and is a member of Developmental Therapeutics and Melanoma Programs

Transcript:
My name is Sun Hur. I’m a part of the department of medicine in Children’s Hospital. In particular, in the program in Cellular Molecular Medicine. I am also part of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

I just joined the DF/HCC especially the programs of Developmental Therapeutics and Melanoma. I was interested in joining these programs because my research is on the innate immune signaling pathway, and I thought that collaboration would actually really benefit my research.  

My research is on innate immune mechanisms of sensing for a nucleic acid. Although these are part of the innate immune pathway developed for antiviral or anti pathogen, recent studies have shown that these pathways actually are important in cancer immunotherapy. So for example, the MDA5 pathway that we have been studying, we are targeting this pathway and activating a system shown to have greatly enhanced the cancer immunotherapy effectiveness. So this is one area that I am interested in moving forward, developing agonists for these receptors for the treatment of cancer immunotherapy or the treatment of melanoma. Also, we are interested in developing antagonists for these receptors for the purpose of applying it to inflammatory disorders such as lupus where these receptors have been implicated.